Cocrystal Pharma Inc (COCP)

[joe_techi]

I suspect insiders will buy a bunch soon and the pps will increase. Technically, last we heard (I think)

CC-31244 (HCV Non-Nucleoside Polymerase Inhibitor - NNI). IND enabling studies have been completed. The preclinical safety profile and antiviral activity of this molecule developed using our crystallization technology continues to indicate the potential to be a best-in-class pan-genotypic HCV NNI. The company remains on track to initiate human clinical trials in the first half of 2016.

CC-1845 (HCV Nucleotide Polymerase Inhibitor). The company is conducting pre-clinical characterization work on CC-1845 and a series of nucleotides and their isomers. The current goal is to select a lead compound for IND-enabling studies in the second half of 2016.